Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma

Gene Therapy volume 19, pages 734–741 (2012)Cite this article

Abstract

Dacarbazine (DTIC) is one of the most popular alkylating agents used for the treatment of malignant melanoma. DTIC induces apoptosis of melanoma cells via double-strand breaks (DSBs). Melanoma cells, however, tend to increase their expression of DNA repair molecules in order to be resistant to DTIC. Here, we show that DTIC increases expression of Rad51, but not Ku70, in a cultured B16-F10 mouse melanoma cell line in dose- and time-dependent manners. On introducing Rad51 short interfering RNA (siRNA) with the hemagglutinating virus of Japan envelope (HVJ-E) to B16-F10 cells, DSBs induced by DTIC treatment were not efficiently repaired and resulted in enhanced apoptotic cell death. Colony formation of B16-F10 cells that received Rad51 siRNA was significantly decreased by DTIC treatment as compared with cells that received scramble siRNA. In melanoma-bearing mice, the combination of three intratumoral injections of HVJ-E containing Rad51 siRNA and five intraperitoneal injections of DTIC at a clinical dose synergistically suppressed the tumors. Moreover, HVJ-E demonstrated anti-tumor immunity by inducing cytotoxic T lymphocytes to B16-F10 cells on administration of DTIC. These results suggest that the combination of chemotherapy with HVJ-E containing therapeutic molecules will provide a promising therapeutic strategy for patients bearing malignant tumors resistant to chemotherapeutic agents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Atkins MB, Buzaid AC, Houghton AN . Systemic chemotherapy and biochemotherapy. In: Balch CM et al. (eds). Cutaneous Melanoma, 4th edn. Quality Medical Publishing: St Louis, 2003, pp 589–604.

    Google Scholar 

  2. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745–2751.

    Article  CAS  Google Scholar 

  3. Huncharek M, Caubet JF, McGarry R . Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75–81.

    Article  CAS  Google Scholar 

  4. Tom C, Reg F, Bernadette C, Malcolm M . Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000; 2: CD001215.

  5. Peter B, Stephen CW . Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 1998; 23: 247–251.

    Article  Google Scholar 

  6. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000; 19: 2791–2795.

    Article  CAS  Google Scholar 

  7. John T . The Rad51 gene family, genetic instability and cancer. Cancer Lett 2005; 219: 125–135.

    Article  Google Scholar 

  8. Makoto I, Seiji Y, Keisuke N, Kazuya H, Hiraoka K, Tamai K et al. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7: 1044–1052.

    Article  Google Scholar 

  9. Jonathan AFH, Juehui L, Zhu QS, Bolshakov SV, Li L, Pisters PW et al. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 2007; 6: 1651–1659.

    Google Scholar 

  10. Elke R, Karen S, Susanne F, Vanessa S, Schweiger S, Haaf T et al. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002; 62: 219–225.

    Google Scholar 

  11. Kondo Y, Fushikida K, Fujieda T, Sakai K, Miyata K, Kato F et al. Efficient delivery of antibody into living cells using a novel HVJ envelope vector system. J Immunol Meth 2008; 332: 10–17.

    Article  CAS  Google Scholar 

  12. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6: 219–226.

    Article  CAS  Google Scholar 

  13. Takami Y, Nakagami H, Morishita R, Katsuya T, Cui TX, Ichikawa T et al. Ubiquitin carboxy-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-κB activation. Arterioscler Thromb Vasc Biol 2007; 27: 2184–2190.

    Article  CAS  Google Scholar 

  14. Kurooka M, Kaneda Y . Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007; 67: 227–236.

    Article  CAS  Google Scholar 

  15. Fujuhara A, Kurooka M, Miki T, Kaneda Y . Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008; 57: 73–84.

    Article  Google Scholar 

  16. Matsuda M, Yamamoto T, Matsumura A, Kaneda Y . Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. Gene Therapy 2009; 16: 1465–1476.

    Article  CAS  Google Scholar 

  17. Emmy PR, Duane RP, Ann HO, Ivanova VS, Bonner WM . DNA double-strand breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858–5868.

    Article  Google Scholar 

  18. Thomas S, Sarah AW, Karen C, Goodarzi AA, Petermann E, Concannon P et al. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO 2006; 25: 5775–5782.

    Article  Google Scholar 

  19. Ashby JM, Xuetong S . DNA repair in the context of chromatin. Cell Cycle 2005; 4: 568–571.

    Google Scholar 

  20. Christoph H, Barbara P, Christiane T, Winter D, Fink D, Kovacic B et al. Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol 2005; 124: 1300–1307.

    Article  Google Scholar 

  21. Emma B, Derek JR, Bin-Bing SZ, Kum KK . Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009; 15: 6314–6320.

    Article  Google Scholar 

  22. Nicola JC . PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005; 15: 603–617.

    Google Scholar 

  23. Christopher MH, Andrei S, Vera G . Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA 2008; 105: 20810–20815.

    Article  Google Scholar 

  24. Jen-Chung K, Shih-Ci C, Chau-Ming C, Wang LH, Hong JH, Jheng MY et al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 2008; 29: 1448–1458.

    Article  Google Scholar 

  25. Artur S, Christoph S, Gregory T, Nieborowska-Skorska M, Hoser G, Nowicki MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795–806.

    Article  Google Scholar 

  26. Jeffery SR, Kristin B, William EB, Cerra MA, Oswaid KA, Camphausen K et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003; 63: 7377–7383.

    Google Scholar 

  27. Roman T, kerstin F, John T, Kaina B . Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett 2006; 239: 305–313.

    Article  Google Scholar 

  28. Bolderson E, Richard DJ, Zhou BBS, Khanna KK . Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 2009; 15: 6314–6320.

    Article  CAS  Google Scholar 

  29. Eric W, David JC . The endless tale of non-homologous end-joining. Cell Res 2008; 18: 114–124.

    Article  Google Scholar 

  30. Olszewska-Slonina DM, Styczynisk J, Drewa TA, Olszewski KJ, Czajkowski R . B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment. Acta Pol Pharm 2005; 62: 473–483.

    CAS  PubMed  Google Scholar 

  31. Min H, Ze-Hong M, Hong Z, Yu-Jun C, Wei L, Jian D . Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther 2008; 7: 1440–1449.

    Article  Google Scholar 

  32. Kim J, Kim PH, Yoo JY, Yoon AR, Choi HJ, Seong J et al. Double E1B 19kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect. Gene Therapy 2009; 16: 1111–1121.

    Article  CAS  Google Scholar 

  33. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26: 5748–5754.

    Article  CAS  Google Scholar 

  34. Masayuki S, Masumi H, Yasumitsu T, Takano TY, Nakatsu Y, Tsuzuki T et al. Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis. Carcinogenesis 2007; 28: 2657–2663.

    Article  Google Scholar 

  35. Saga K, Tamai K, Kawachi M, Shimbo T, Fujita H, Yamazaki T et al. Functional modification of Sendai virus by siRNA. J Biotechnol 2008; 133: 386–394.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Northern Osaka (Saito) Biomedical Knowledge-Based Cluster Creation Project, Scientific Research (B) Fund by the Ministry of Education, Culture, Sports, Science and Technology of Japan and grants from the Ministry of Health, Labor, and Welfare of Japan.

Author information

Authors and Affiliations

  1. Division of Gene Therapy Science,

    E Kiyohara, K Tamai & Y Kaneda

  2. Osaka University Graduate School of Medicine, Osaka, Japan

    E Kiyohara, K Tamai & Y Kaneda

  3. Department of Dermatology, Graduate School of Medicine, Osaka University, Osaka, Japan

    E Kiyohara, K Tamai & I Katayama

Authors
  1. E Kiyohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Tamai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Katayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Kaneda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Kaneda.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiyohara, E., Tamai, K., Katayama, I. et al. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Gene Ther 19, 734–741 (2012). https://doi.org/10.1038/gt.2011.123

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2011.123

Keywords

This article is cited by

Search

Advanced search

Quick links